$SEPN News
Last published 1d ago
- 1d agoSEPNGuggenheim 3rd Annual Healthcare Innovation Conference - SEPTERNA INCEarnings Call TranscriptsAll right. Thanks, everybody, for joining us at Guggenheim's third annual Healthcare Innovations Conference. I'm Seamus Fernandez, one of the senior biotech analysts here at Guggeheim, and I'm really pleased to be joined
- 2d agoSEPNSepterna, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoSEPNSepterna Highlights Business Progress and Reports Third Quarter 2026 Financial ResultsGlobeNewswirePhase 1 Clinical Trial for PTH1R Agonist SEP-479 Ongoing; SAD / MAD Data Expected in Q1 2027
- 2d agoSEPNSepterna Highlights Business Progress and Reports Third Quarter 2026 Financial ResultsGlobeNewswirePhase 1 Clinical Trial for PTH1R Agonist SEP-479 Ongoing; SAD / MAD Data Expected in Q1 2027 Plans to Initiate Phase 1 Clinical Trial of Newly Selected Oral TSHR NAM Development Candidate SEP-204 in Q1 2027 Cash
- 1w agoSEPNSepterna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual MeetingGlobeNewswirePotent, selective TSHR NAM with pre-clinical activity demonstrated across biochemical, thyroid and ocular endpoints Favorable PK profile anticipated to support once-daily oral dosing in humans Phase 1 clinical trial
- 1w agoSEPNSepterna to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today
- 2mo agoSEPNSepterna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), today announced that the Company granted a non-qualified stock option to purchase up to 275,000 shares of the Company’s
- 2mo agoSEPNSepterna to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today
- 2mo agoSEPNSepterna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today
- 3mo agoSEPNSepterna Highlights Business Progress and Reports Second Quarter 2026 Financial ResultsGlobeNewswirePhase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash Position of $516.5
- 5mo agoSEPNSepterna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual MeetingBusiness WireSepterna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization of
- 6mo agoSEPN2026 GLOBAL HEALTHCARE CONFERENCE - SEPTERNA INCEarnings Call Transcriptsthe end of our first day of our annual healthcare conference in a very toasty Las Vegas. I'm very pleased to have join us right now Jeff Feiner of Septerna, who will be providing us with a presentation. Jeff? Okay. Yeah,
- 6mo agoSEPNSepterna Highlights Business Progress and Reports First Quarter 2026 Financial ResultsGlobeNewswireCompelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Phase 1 Clinical Trial Initiated for
- 6mo agoSEPNSepterna to Present at Bank of America Securities Health Care ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced
- 6mo ago.DJI.SPXBAUAL+6Ceasefire extension, Best Buy's new CEO, Amazon's GLP-1 push and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
- 6mo agoHIMSAMGNVKTXSEPN+3Amazon launches GLP-1 weight loss program, promising 'fast, convenient' accessCNBCThrough Amazon Pharmacy, patients will be able to access medications including Novo Nordisk's Wegovy as well as newer oral GLP-1 options.
- 7mo agoSEPNSepterna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of HypoparathyroidismGlobeNewswireTrial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers Data Anticipated in Late 2026 or Early 2027 SOUTH SAN FRANCISCO, Calif., April 13, 2026
- 8mo agoSEPNSepterna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireCompelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Advancing SEP-479 (PTH1R Agonist) Toward
- 8mo agoSEPNSEP-631 Phase 1 Results Conference Call - SEPTERNA INCEarnings Call TranscriptsGood day. Thank you for standing by. Welcome to Subterna's SEP 631 Phase 1 Results Conference 1 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a
- 8mo agoSEPNSepterna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development StrategyGlobeNewswireSEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses Studied with an
- 8mo agoSEPNSepterna to Present at TD Cowen 46th Annual Health Care ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced
- 9mo agoSEPNSepterna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced
- 9mo agoSEPNSepterna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today
- 10mo agoSEPNSepterna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today
- 10mo agoSEPNSepterna to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today
- 11mo agoSEPNSepterna to Participate in 8th Annual Evercore Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today
- 1y agoSEPNSepterna Highlights Company Progress and Reports Third Quarter 2025 Financial ResultsGlobeNewswireSEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate SEP-631 (MRGPRX2 NAM) Phase 1 Clinical Trial in Healthy Volunteers Ongoing Robust Financial Position of $561.6 Million Expected to Support
- 1y agoSEPNSepterna to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today
- 1y agoSEPNSepterna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc.
- 1y agoSEPNSepterna to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today
- 1y agoSEPNSepterna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven DiseasesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today
- 1y agoSEPNSepterna Highlights Business Progress and Reports Second Quarter 2025 Financial ResultsGlobeNewswireAdvancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to
- 1y agoSEPNSepterna to Present at Jefferies Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey
- 1y agoSEPNSepterna Highlights Business Progress and Reports First Quarter 2025 Financial ResultsGlobeNewswireAnnounced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral Small Molecule
- 1y agoSEPNSepterna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswirePreclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases,
- 1y agoSEPNSepterna to Present at TD Cowen 45th Annual Health Care ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that
- 1y agoSEPNKirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of InvestorsGlobeNewswireNEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Septerna, Inc. ("Septerna" or the "Company") (NASDAQ:SEPN). The investigation concerns whether
- 1y agoSEPNSepterna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R AgonistGlobeNewswireTrial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures relative to SEP-786
- 1y agoSEPNSepterna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced
- 1y agoSEPNSepterna to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D.,
- 1y agoSEPNSepterna Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswireDeep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule for
- 2y agoSEPNSepterna Announces Closing of $331.2 Million Upsized Initial Public OfferingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug
- 2y agoSEPNSepterna Prices Upsized Initial Public OfferingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug